Integration of cytogenetic aberrations and in silico pathway enrichment identifies novel candidate genes in esophageal squamous cell carcinoma

Table 1 Cytogenetic aberrations in patients with esophageal cancer and controls, mean ± SD

Item	Patients (n = 135)	Controls (n = 135)	P value
Mean (%) aberrant metaphases	27.45 ± 9.7	11.6 ± 4.1	< 0.0001
Mean (%) metaphases with structural aberrations	8.6 ± 5.7	4.7 ± 2.7	< 0.0001
Mean (%) metaphases with numerical aberrations	15.4 ± 7.1	5.8 ± 3.1	< 0.0001
Mean (%) metaphases with both structural and numerical aberrations	3.3 ± 2.7	2.3 ± 0.9	< 0.0001